Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: RVX-208
  • Price: $350.0/100mg $600.0/250mg $1100.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
1044870-39-4 1044871-04-6
14145-42-7 1002304-34-8
14913-50-9 627536-09-8
100999-26-6 2245942-72-5
13966-28-4 512-63-0
1158522-08-7 940364-43-2
2573850-20-9 134104-43-1
131615-57-1 6906-52-1
930439-75-1 1018584-77-4
2227902-34-1 2416229-52-0

1044870-39-4

1044870-39-4 structure
1044870-39-4 structure
  • Name: RVX-208
  • Chemical Name: 2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one
  • CAS Number: 1044870-39-4
  • Molecular Formula: C20H22N2O5
  • Molecular Weight: 370.399
  • Catalog: Biochemical Inhibitor Epigenetics Epigenetic Reader Domain Inhibitor
  • Create Date: 2018-02-22 08:00:00
  • Modify Date: 2024-01-05 20:18:13
  • Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87±10 μM and 0.51±0.041 μM for BD1 and BD2, respectively.
Name 2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one
Synonyms UNII:8R4A7GDZ1D
2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1H-quinazolin-4-one
4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-
2-[4-(2-Hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-4(1H)-quinazolinone
Apabetalone
RVX-208
Description Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87±10 μM and 0.51±0.041 μM for BD1 and BD2, respectively.
Related Catalog
Target

IC50: 510±41 nM (BD2), 87±10 μM (BD1)[1]

In Vitro Apabetalone (RVX-208) competes with binding of an acetylated histone peptide to tandem BD1 BD2 protein constructs of the four BET proteins, with IC50s between 0.5 and 1.8 µM. Apabetalone increases the production of ApoA-I in hepatocytes in vitro, which results in increased high density lipoprotein cholesterol (HDL-C). Apabetalone selectively binds to bromodomains of the BET (Bromodomain and Extra Terminal) family, competing for a site bound by the endogenous ligand, acetylated lysine, and that this accounts for its pharmacological activity. Apabetalone increases Apolipoprotein A-I (ApoA-I) production through an epigenetic mechanism and suggests that BET inhibition may be a promising new approach to the treatment of atherosclerosis. Apabetalone increases ApoA-I expression in liver cells[2].
In Vivo In the atherosclerosis prophylactic treatment study design, mice are fed a Western diet concurrent with the treatment with 150 mg/kg/dose b.i.d. for 12 weeks. Mice are sacrificed at 12 weeks after treatment. There is a progressive increase in body weight in both the vehicle treated as well as the Apabetalone (RVX-208) treated groups. However, there is only an increase of 4 g (from 24 g to 28 g) body weight after 12 weeks on Western diet in the Apabetalone treated group whereas this increase is found to be 9 g (25 g-34 g) in the vehicle treated group. The significant decrease in body weight gain in Apabetalone treated mice is not due to decreased feed consumption, suggesting a positive attribute of the molecule. Plasma lipid measurements are done at 6 weeks and 12 weeks of treatment with either the vehicle or Apabetalone. Compared to the vehicle control animals, Apabetalone treated mice show significant increase (~200%) in the levels of HDL-C at 6 weeks of treatment, which is sustained until end of the study (12 weeks)[3].
Cell Assay Huh7 cells are plated at 23,000/well in a 96 well plate in DMEM+10% FBS before allowing to grow overnight. Cells are treated with compounds for 48 h in 0.1% DMSO with or without 5 µM Actinomycin D. U937 cells are differentiated for 3 days in 60 ng/mL PMA, 32,000 cells/well in 96-well format. Cells are then treated with compound in 0.1% DMSO in RPMI media+10% FBS, and after 1 h, lipopolysaccharide is added to the cells at 1 µg/mL for 3 hours[2].
Animal Admin Mice[3] Seven to eight week old male ApoE-/- mice are used. Based on the body weight and lipid values, mice are divided into 2 groups (n=12): group 1, vehicle; and group 2, test agent, Apabetalone. Mice are then switched to Western diet (0.15% cholesterol and 42% calories from fat) and concurrently treated orally by gavage with either vehicle or the test agent, Apabetalone (150 mg/kg/dose b.i.d) for 12 weeks. After 6 week of treatment, an interim blood draw is done to monitor serum lipid levels. After 12 weeks of treatment mice are sacrificed to measure blood lipid parameters, aortic lesion, and liver and aortic RNA. Eight mice are used for enface (aortic plaque) analysis, 4 mice for tissue collection for mRNA and all 12 mice used for aortic sinus lesion area measurement.
References

[1]. Picaud S, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9.

[2]. McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013 Dec 31;8(12):e83190.

[3]. Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014 Sep;236(1):91-100.
Density 1.3±0.1 g/cm3
Molecular Formula C20H22N2O5
Molecular Weight 370.399
Exact Mass 370.152863
PSA 93.67000
LogP 2.04
Index of Refraction 1.596
Storage condition -20℃
HS Code 2933990090
1039948-89-4 structure

1039948-89-4

63920-73-0 structure

63920-73-0

~78%

1044870-39-4 structure

1044870-39-4

Literature: WO2009/158404 A1, ; Page/Page column 16-17 ; WO 2009/158404 A1
1044872-73-2 structure

1044872-73-2

63920-73-0 structure

63920-73-0

~39%

1044870-39-4 structure

1044870-39-4

Literature: US2008/188467 A1, ; Page/Page column 33 ; US 20080188467 A1
21544-81-0 structure

21544-81-0

~%

1044870-39-4 structure

1044870-39-4

Literature: US2013/281397 A1, ;
40891-33-6 structure

40891-33-6

~%

1044870-39-4 structure

1044870-39-4

Literature: US2013/281397 A1, ;
10272-07-8 structure

10272-07-8

~%

1044870-39-4 structure

1044870-39-4

Literature: US2013/281397 A1, ;
2233-18-3 structure

2233-18-3

~%

1044870-39-4 structure

1044870-39-4

Literature: US2013/281397 A1, ;
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:1044870-39-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1044870-39-4 | Chemsrc address: https://www.chemsrc.com/en/baike/598725.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved